ClinicalTrials.gg
TerminatedNCT06083454Updated Nov 10, 2026Results posted

Ascorbate With Durvalumab in Non-Small Cell Lung Cancer (NSCLC)

A Phase 1 interventional study of Durvalumab and Pharmacological ascorbate in Non-small Cell Lung Cancer, sponsored by William Zeitler. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by William Zeitler · Phase 1, Interventional, and Treatment

How we know · 7 judgments · 2 readings being read again

Why this study was terminated
funding change
Updated Nov 10, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
1
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung — 16 open to participants now, 37 under way, 11 of them phase 3. durvalumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
89th of 94
1 · median 74
Started
2023
with 2 others
Phase 1
13 of 94
1 open now
Registered
84th of 94
by date

Among the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, this one is the 89th largest by enrollment, is one of 3 that started in 2023, is one of 13 in phase 1, and was the 84th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

16 of the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About durvalumab

durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a descriptive, proof of concept, open-label, randomized, 3-arm, window of opportunity trial to evaluate the immunomodulatory role of pharmacological ascorbate with Durvalumab

Read the detailed description

Participants in this research study have stage I Non-Small Cell Lung Cancer (NSCLC) that was found to be suitable for surgery as a first line treatment.

The usual treatment for this disease is to remove the tumor with surgery, and then evaluate after surgery if other additional treatments such as chemotherapy or targeted therapy are needed.

The purpose of this research study is to compare three different ways of treating stage 1 NSCLC, to see if adding treatment before surgery can reduce the chance of the tumor recurring after surgical removal.

In this study, patients will be randomly assigned to one of three treatments:

  • Durvalumab followed by surgical resection of the tumor.
  • Durvalumab plus ascorbate (also known as vitamin C), followed by surgical resection of the tumor.
  • Surgical resection alone. No therapy prior to surgery. This is the same as standard care (SOC) for this disease.
03

Conditions studied

  • Non-small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Capable of giving signed which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
  • Age > 18 years at time of study entry regardless of gender or ethnic/racial background.
  • or cytologically confirmed non-small cell lung cancer
  • Clinical stage I with tumor size >1 cm to 4 cm (either T1b or T1c or T2a and N0 M0) according to American Joint Committee on Cancer 8th edition
  • Surgically resectable with adequate lung functions to undergo surgery as determined by thoracic surgeon.
  • (ECOG) performance status of 0 or 1
  • Body weight >30 kg
  • Adequate normal organ and marrow function as defined below:

    • ≥9.0 g/dL
    • (ANC) ≥1.0 × 109 /L
    • count ≥75 × 109/L
    • Serum ≤1.5 x institutional (ULN). This will not apply to patients with confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will be allowed only in consultation with their physician.>>
    • (SGOT)/ALT (SGPT) ≤2.5 x institutional upper limit of normal.
    • Measured (CL) ≥50 mL/min or Calculated creatinine CL≥50 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for determination of creatinine clearance:

Males:

Creatinine CL (mL/min)= Weight (kg) x (140 - Age) divided by 72 x serum creatinine (mg/dL)

Females:

Creatinine CL (mL/min)= Weight (kg) x (140 - Age) x 0.85 divided by 72 x serum creatinine (mg/dL)

  • Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.
  • Must have a of at least 12 weeks
  • Female subjects of and non-sterilized male subjects who intend to be sexually active during the study must agree to use a highly effective method of from the time of screening, throughout the total duration of the drug treatment, and during the 90-day post-drug .
  • Evidence of status or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply: Women 1 year ago, had chemotherapy-induced menopause with last menses >1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).

Exclusion criteria

Exclusion Criteria:

Patients should not enter the study if any of the following exclusion criteria are fulfilled:

  • Participation in another clinical study with an product during the last 4 weeks prior to randomization
  • Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study
  • Prior systemic therapy for early-stage NSCLC that is under consideration for thisstudy.
  • Any unresolved toxicity Grade ≥2 from previous anticancer therapy with the exception of alopecia, vitiligo, clinically non-significant labs values (e.g., lymphopenia), and the laboratory values defined in the inclusion criteria

    1. Patients with Grade ≥2 neuropathy will be evaluated on a case-by-case basis after consultation with the Study Physician.
    2. Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab may be included only after consultation with the Study Physician.
  • Any concurrent chemotherapy, IP, biologic, or hormonal therapy for cancer treatment.Concurrent use of hormonal therapy for non-cancer-related conditions (e.g., hormone replacement therapy) is acceptable.
  • Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of the first dose of study drug
  • Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of IP.
  • History of allogenic organ transplantation.
  • Active or prior documented or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this criterion:

    1. Patients with vitiligo or alopecia
    2. Patients with hypothyroidism (e.g., following Hashimoto syndrome) clinically stable on hormone replacement
    3. Any chronic skin condition that does not require systemic therapy
    4. Patients without active disease in the last 5 years may be included but only after consultation with the Study Physician
    5. Patients with celiac disease controlled by diet alone
    6. Patients with type 2 DM (insulin dependent or independent) are allowed.
  • Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written
  • History of another primary except for

    1. Malignancy treated with curative intent and with no known active disease ≥2 years before the first dose of IP and of low potential risk for recurrence
    2. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
    3. Adequately treated non-melanoma skin cancer, in situ bladder, gastric, breast, colon or cervical cancers/dysplasia's, noninvasive colonic polyps, superficial bladdertumors,
    4. Monoclonal B-cell lymphocytosis, or monoclonal gammopathy of undetermined significance.
  • Known to have nodal or distant
  • Mean corrected for heart rate using Fridericia's formula (QTcF) ≥470 ms
  • History of active primary immunodeficiency
  • Known history of active hepatitis infection, positive virus (HCV) antibody, virus (HBV) surface antigen (HBsAg) or HBV core antibody (anti-HBc), at screening. Participants with a past or resolved HBV infection (defined as the presence of antiHBc and absence of HBsAg) are eligible. Participants positive for HCV antibody are eligible only if polymerase chain reaction is negative for HCV RNA
  • Known to have tested positive for (HIV) (positive HIV 1/2 antibodies) or active tuberculosis infection (clinical evaluation that may include clinical history, physical examination and radiographic findings, or tuberculosis testing in line with local practice).
  • Current or prior use of medication within 14 days before the first dose of durvalumab. The following are exceptions to this criterion:

    1. Intranasal, inhaled, topical , or local steroid injections (e.g., intra articular injection)
    2. Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent
    3. Steroids as premedication for reactions (e.g., CT scan premedication)
  • Receipt of within 30 days prior to the first dose of IP. Note:

Patients, if enrolled, should not receive live vaccine while receiving IP and up to 30 days after the last dose of IP.

  • Participant that is pregnant or breastfeeding.
  • Known allergy or hypersensitivity to any of the study drugs or any of the study drug .
  • Prior randomization or treatment in a previous durvalumab clinical study regardless of treatment Arm assignment.
  • Prior anti , PD-L1 and CTLA-4 therapy in the last 2 years

    1. Experienced a toxicity that led to permanent discontinuation of prior immunotherapy.
    2. All AEs while receiving prior immunotherapy must have completely resolved or resolved to baseline prior to screening for this study.
    3. Experienced a ≥Grade 3 immune related AE or an immune related neurologic or ocular AE of any grade while receiving prior immunotherapy. NOTE: Patients with endocrine AE of ≤Grade 2 are permitted to enroll if they are stably maintained on appropriate replacement therapy and are asymptomatic.
    4. Required the use of additional immunosuppression other than corticosteroids for the management of an AE, experienced recurrence of an AE if re-challenged, and currently require maintenance doses of > 10 mg prednisone or equivalent per day.
  • Judgment by the investigator that the patient is unsuitable to participate in the study and the patient is unlikely to comply with study procedures, restrictions and requirements.
  • Known allergy or hypersensitivity to IP or any excipient.
  • active infection requiring systemic therapy
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    Durvalumab as monotherapy

    Two cycles of Durvalumab 1500 mg every 3 weeks, as monotherapy

    Drug: Durvalumab

  • Experimental
    Combination of pharmacological ascorbate plus Durvalumab

    Combination of pharmacological ascorbate 75 grams intravenously three times a week x 4 weeks plus Durvalumab 1500 mg every 3 weeks for two cycles

    Drug: Durvalumab · Drug: Pharmacological ascorbate

  • Active comparator
    Control (no neoadjuvant therapy)

    Serve as control and patients will not receive any neoadjuvant therapy before going to surgery. Once randomize, they can go to surgery without any delays.

    Procedure: Surgery (SOC)

Interventions

  • Given intravenous (IV) infusion as monotherapy or in combination with pharmacological ascorbate

  • DrugAscorbic AcidBeing read again: the record changed after it was read.Studies of Ascorbic AcidAscorbic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given intravenously in combination with Durvalumab

  • ProcedureSurgery (SOC)

    Surgery SOC

06

What researchers measure

Primary outcomes

  1. CD8+ T Cells Quantified as the Percentage of Lymphocytes That Are CD8+ T Cells

    Determine if Pharmacological Ascorbate and durvalumab can potentiate or enhance an immune response in the NSCLC tumor-microenvironment compared to durvalumab alone. This will be evaluated in the surgically resected specimens of patients after receiving neoadjuvant therapy. CD8+ T cells will be quantified as the percentage of lymphocytes that are CD8+ T cells

    Time frame: Following surgical resection which will be performed during weeks 5-9 from the day of randomization.

Secondary outcomes

  1. Number of Dose Limiting Toxicities (DLTs) and Adverse Events (AEs) Per CTCAE v5

    Assess safety and tolerability of the combination of Pharmacological Ascorbate and Durvalumab in the neoadjuvant setting (Arm:2)

    Time frame: Throughout the treatment period, 4 weeks

  2. Pathologic Complete Response (pCR) Rate

    The proportion of patients with a pathologic complete response, defined as no viable tumor.

    Time frame: Up to three years following completion of treatment

  3. Major Pathologic Response (MPR) Rate

    The proportion of patients with a major pathologic response, defined as residual viable tumor of 10% or less.

    Time frame: Up to three years following completion of treatment

  4. Event-Free Survival

    Time from randomization to progression of disease that precludes surgery, local or distant recurrence, or death due to any cause.

    Time frame: Up to three years following completion of treatment

  5. Overall Survival

    Time from randomization to death due to any cause.

    Time frame: Up to three years following completion of treatment

07

Results

Posted Nov 10, 2026
Limitations and caveats
The study was terminated before reaching the planned enrollment of 36 participants because of funding limitations. One participant completed protocol treatment; however, the planned immune analyses were not performed. Therefore, no primary efficacy, pathologic response, or survival outcome data were available for analysis, and no conclusions regarding efficacy or biologic activity can be drawn.

Participant flow

Participant flow — Overall Study
MilestoneDurvalumab as MonotherapyCombination of Pharmacological Ascorbate Plus DurvalumabControl (no Neoadjuvant Therapy)
Started010
Completed010
Not completed000

Outcome measures

PrimaryCD8+ T Cells Quantified as the Percentage of Lymphocytes That Are CD8+ T Cells

Determine if Pharmacological Ascorbate and durvalumab can potentiate or enhance an immune response in the NSCLC tumor-microenvironment compared to durvalumab alone. This will be evaluated in the surgically resected specimens of patients after receiving neoadjuvant therapy. CD8+ T cells will be quantified as the percentage of lymphocytes that are CD8+ T cells

Time frame:
Following surgical resection which will be performed during weeks 5-9 from the day of randomization.

No measurements were reported for this outcome.

SecondaryNumber of Dose Limiting Toxicities (DLTs) and Adverse Events (AEs) Per CTCAE v5

Assess safety and tolerability of the combination of Pharmacological Ascorbate and Durvalumab in the neoadjuvant setting (Arm:2)

Time frame:
Throughout the treatment period, 4 weeks
Reported as:
Number · events
Number of Dose Limiting Toxicities (DLTs) and Adverse Events (AEs) Per CTCAE v5
eventsDurvalumab as MonotherapyCombination of Pharmacological Ascorbate Plus DurvalumabControl (no Neoadjuvant Therapy)
Number of DLTs—0—
Number of AEs—6—
SecondaryPathologic Complete Response (pCR) Rate

The proportion of patients with a pathologic complete response, defined as no viable tumor.

Time frame:
Up to three years following completion of treatment

No measurements were reported for this outcome.

SecondaryMajor Pathologic Response (MPR) Rate

The proportion of patients with a major pathologic response, defined as residual viable tumor of 10% or less.

Time frame:
Up to three years following completion of treatment

No measurements were reported for this outcome.

SecondaryEvent-Free Survival

Time from randomization to progression of disease that precludes surgery, local or distant recurrence, or death due to any cause.

Time frame:
Up to three years following completion of treatment

No measurements were reported for this outcome.

SecondaryOverall Survival

Time from randomization to death due to any cause.

Time frame:
Up to three years following completion of treatment

No measurements were reported for this outcome.

Adverse events

Collected over Adverse events were collected from the beginning of study treatment throughout the treatment period, up to 4 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Durvalumab as Monotherapy———
Combination of Pharmacological Ascorbate Plus Durvalumab0/1 (0%)0/1 (0%)1/1 (100%)
Control (no Neoadjuvant Therapy)———
Most frequent other events
Most frequent other events
EventDurvalumab as MonotherapyCombination of Pharmacological Ascorbate Plus DurvalumabControl (no Neoadjuvant Therapy)
AnemiaBlood and lymphatic system disorders—1/1—
ConstipationGastrointestinal disorders—1/1—
Abdominal PainGastrointestinal disorders—1/1—
Non-cardiac chest painGeneral disorders—1/1—
HyponatremiaMetabolism and nutrition disorders—1/1—

Baseline characteristics

One participant enrolled to Combination of pharmacological ascorbate plus Durvalumab (Arm 2) and completed treatment per protocol. No participants were enrolled in the other arms, and the study was terminated early due to funding.

Age, Categorical
Age, Categorical(Participants)Durvalumab as MonotherapyCombination of Pharmacological Ascorbate Plus DurvalumabControl (no Neoadjuvant Therapy)Total
<=18 years0000
Between 18 and 65 years0101
>=65 years0000
Age, Continuous
Age, Continuous(years)Durvalumab as MonotherapyCombination of Pharmacological Ascorbate Plus DurvalumabControl (no Neoadjuvant Therapy)Total
Mean—60 (60 to 60)—60 (60 to 60)
Sex: Female, Male
Sex: Female, Male(Participants)Durvalumab as MonotherapyCombination of Pharmacological Ascorbate Plus DurvalumabControl (no Neoadjuvant Therapy)Total
Female—1—1
Male—0—0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Durvalumab as MonotherapyCombination of Pharmacological Ascorbate Plus DurvalumabControl (no Neoadjuvant Therapy)Total
Hispanic or Latino—1—1
Not Hispanic or Latino—0—0
Unknown or Not Reported—0—0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Durvalumab as MonotherapyCombination of Pharmacological Ascorbate Plus DurvalumabControl (no Neoadjuvant Therapy)Total
American Indian or Alaska Native—0—0
Asian—0—0
Native Hawaiian or Other Pacific Islander—0—0
Black or African American—0—0
White—0—0
More than one race—0—0
Unknown or Not Reported—1—1
Region of Enrollment
Region of Enrollment(participants)Durvalumab as MonotherapyCombination of Pharmacological Ascorbate Plus DurvalumabControl (no Neoadjuvant Therapy)Total
United States—1—1
08

Study locations

1 site
  • University of Iowa
    Iowa City, Iowa 52242, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2023 to primary completion in Apr 2025, 17 months.

Results were first posted in Nov 2026, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2023
First posted
Oct 16, 2023
StartActual
Oct 23, 2023
Primary completionActual
Apr 4, 2025
CompletionActual
Jan 9, 2026
Results first posted
Nov 10, 2026
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 10, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedCD8+ T cells quantifiedCells Quantified as the percentagePercentage of lymphocytes that areLymphocytes That Are CD8+ T cellsCellsTime frame: Following surgical resection which will be performed during weeks 5-9 from the day of randomization.
Nov 10, 2026
Secondary outcomes
3 edited
What changed in the outcomes
  • EditedIncidenceNumber of dose limiting toxicitiesDose Limiting Toxicities (DLTs) and adverse eventsAdverse Events (AEs) perPer CTCAE v5Time frame: Throughout the treatment period, 4 weeks
  • EditedPathologic Complete Response (pCR) rateRateTime frame: Up to three years following completion of treatment
  • EditedMajor Pathologic Response (MPR) rateRateTime frame: Up to three years following completion of treatment
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedCD8+ T cells quantifiedCells Quantified as the percentagePercentage of lymphocytes that areLymphocytes That Are CD8+ T cellsCellsTime frame: Following surgical resection which will be performed during weeks 5-9 from the day of randomization.
    Secondary outcomes 3 edited
    What changed in the outcomes
    • EditedIncidenceNumber of dose limiting toxicitiesDose Limiting Toxicities (DLTs) and adverse eventsAdverse Events (AEs) perPer CTCAE v5Time frame: Throughout the treatment period, 4 weeks
    • EditedPathologic Complete Response (pCR) rateRateTime frame: Up to three years following completion of treatment
    • EditedMajor Pathologic Response (MPR) rateRateTime frame: Up to three years following completion of treatment
    + 1 other change: index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06083454
Lead sponsor
William Zeitler
Responsible party
William Zeitler (Clinical Assistant Professor, University of Iowa) — Sponsor-investigator
First posted
Oct 16, 2023
Start date
Oct 23, 2023
Primary completion
Apr 4, 2025
Completion
Jan 9, 2026
Results posted
Nov 10, 2026
Last update
Nov 10, 2026

Study contacts

William Zeitler, MD, MPH
principal investigator · University of Iowa

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Durvalumab

Start the discussion